Direct acting inhibitors of ammoniagenesis: a role in post-TIPS encephalopathy?
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 2
Abstract
A limited number of medications are typically considered for the management of hepatic encephalopathy occurring as a complication of transjugular intrahepatic portosystemic shunt (TIPS) placement. Multiple alternative compounds aimed at disrupting ammoniagenesis are or will soon be available, though their use tends to be limited by a lack of large data sets and of clinical awareness. In this review, we provide a targeted overview of the mechanisms and availability of five anti-ammoniagenic compounds (sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, L-ornithine L-aspartate, and ornithine phenylacetate) identified as possibly useful alternative therapeutic agents for cirrhotic encephalopathy. Three of these medications have been FDA approved for use in congenital urea cycle disorders only, while two are under active investigation for use in cirrhotic patients. In spite of limitations posed by cost and comorbidities, familiarity with these options may prove beneficial in cases refractory to conventional management.
Authors and Affiliations
Nitin K. Ahuja Ahuja, Winston A. Ally, Stephen H. Caldwell
Keywords
Related Articles
- EP ID EP78373
- DOI -
- Views 113
- Downloads 0
Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients
Background. Conflicting data have been reported on the prevalence of liver steatosis, its risk factors and its relationship with fibrosis in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-inf...
Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation
Hepatopulmonary syndrome (HPS) is a complication of portal hypertension (PH) defined by the presence of liver disease, abnormal pulmonary gas exchange and evidence of intrapulmonary vascular dilatations (IPVD) producing...
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain
Background and rational. Telaprevir-based therapy (TBT) has been extensively evaluated in clinical trials. So we designed a study to compare the efficacy and safety of TBT between patients with moderate fibrosis and thos...
Hepatic carcinosarcoma: clinicopathologic features and a review of the literature
Hepatic carcinosarcoma (HCS) is defined as a malignant tumor containing an intimate mixture of carcinomatous and sarcomatous elements. Here, we report the case of a 72-year-old man who developed HCS from an otherwise nor...
MEXICAN CONSENSUS ON THE DIAGNOSIS AND MANAGEMENT OF HEPATITIS C INFECTION